ArticleCardiovascular research2026
Integrative transcriptomic profiling links telomere dysfunction to cGAS-STING activation in heart failure signatures in mice and humans.
Article in Cardiovascular research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- cGAS-STING signaling in aging and age-related diseases: therapeutic promise and precaution.Archives of pharmacal research · 2026Review
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
Abstract
aimsCardiomyocyte telomere shortening is evident during heart failure pathogenesis. Conversely, mice with engineered telomerase deficiency develop myocardial dysfunction accompanied by p53 activation and mitochondrial repression. We aimed to address fundamental gaps in knowledge: whether cardiac dysfunction in mice lacking telomerase components arises from myocardial-intrinsic effects or systemic consequences of telomere shortening, which broader transcriptional programs follow, and what implications these have for clinical heart failure. METHODS AND
resultsWe generated telomerase-deficient mice until generation 5 (mTRG5) and confirmed shortening telomeres along with increasing cardiac dysfunction by cardiovascular phenotyping and cardiomyocyte mitochondrial function assessment. Transcriptional and regulator analysis confirmed the telomere -p53 -mitochondria axis but extended beyond it, revealing additional involvement of neurohumoral activation, senescence, and inflammation, notably type I interferon signaling. To contextualize these findings, we compared this profile with hypertensive heart failure induced by neurohumoral dysregulation (angiotensin II infusion, nephrectomy, salt overload; ANS) and established a transcriptional hierarchy. In mTRG5 mice, regulators of telomere dysfunction and p53 activation ranked highest by significance and centrality, supporting telomere shortening as the primary upstream driver. Reciprocally, ANS mice showed higher-ranking neurohumoral regulators, indicating these govern secondary pathways. To pursue the strong type I interferon profile, we utilized myocardial profiles of mice lacking three-prime exonuclease 1, an established activator of the cGAS -STING pathway. Matching the profiles, we confirmed pronounced activation of cGAS -STING in mTRG5 mice -and slightly less in ANS mice -providing first evidence for cGAS -STING activation in telomere shortening and heart failure. Integration of the mTRG5 signature with curated transcriptomic datasets from murine and human dilated and ischemic cardiomyopathy revealed robust cross-species and cross-etiology overlap that increased with heart failure severity and decreased with functional recovery.
conclusionThese findings establish telomere dysfunction as a pathogenic driver that engages innate immune signaling via the cGAS -STING pathway, with direct relevance to human heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.